Heart failure: Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure

American Heart Journal

Volumn 165, Issue 6, 2013, Pages

  Curtis, Lesley H ^a,b   Mi, Xiaojuan ^a   Qualls, Laura G ^a   Check, Devon K ^a   Hammill, Bradley G ^a   Hammill, Stephen C ^c   Heidenreich, Paul A ^d   Masoudi, Frederick A ^e   Setoguchi, Soko ^a,b   Hernandez, Adrian F ^a,b   Fonarow, Gregg C ^f  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

AGED; ARTICLE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOME; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; SENSITIVITY ANALYSIS; COMPARATIVE STUDY; ECONOMICS; HEART STROKE VOLUME; HOSPITALIZATION; MORTALITY; MULTICENTER STUDY; PATIENT CARE; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL RATE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CONTINUITY OF PATIENT CARE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MEDICARE; MEDICATION ADHERENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REGISTRIES; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; UNITED STATES;

MLCS; MLOWN;

EID: 84880077072     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.03.007     Document Type: Article

References (22)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
2. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364: 11-21.
3. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
4. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005;112: 39-47.
5. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-65.
6. van Walraven C, Mamdani M, Fang J, et al. Continuity of care and patient outcomes after hospital discharge. J Gen Intern Med 2004; 19:624-31.
7. Coleman EA, Berenson RA. Lost in transition: Challenges and opportunities for improving the quality of transitional care. Ann Intern Med 2004;141:533-6.
8. Hong Y, LaBresh KA. Overview of the American Heart Association "Get with the Guidelines" programs: Coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol 2006;5:179-86.
9. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): Rationale and design. Am Heart J 2004;148: 43-51.
10. Hammill BG, Hernandez AF, Peterson ED, et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 2009;157:995-1000.
11. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
12. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: Primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-96.
13. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. Circ Heart Fail 2008;1:98-106.
14. Margolis J, Gerber RA, Roberts C, Gheorghiade M. Adherence to aldosterone-blocking agents in patients with heart failure. Am J Ther 2010;17:446-54.
15. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303:1716-22.
16. Fonarow GC, Abraham WT, Albert NM, et al. Influence of betablocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;52:190-9.
17. Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004;43:2036-43.
18. Monane M, Bohn RL, Gurwitz JH, et al. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994; 154:433-7.
19. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-12.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
21. Coleman EA, Smith JD, Raha D, et al. Posthospital medication discrepancies: Prevalence and contributing factors. Arch Intern Med 2005;165:1842-7.
22. Curtis LH, Greiner MA, Hammill BG, et al. Representativeness of a national heart failure quality-of-care registry: Comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes 2009;2:377-84.